GASTROClear™ has been granted regulatory approval by China’s National Medical Products Administration (NMPA) as an in vitro diagnostic (IVD) product, becoming the first non-invasive blood test approved for the screening of gastric cancer in China. The test can be used for gastric cancer screening in adults aged 45 to 74 who are at high risk for the disease. This represents an eligible screening population estimated to be over 500 million.

Mirxes International Holding and Xeraya Opportunities Fund PCC formed a new joint venture MyRNA Diagnostics to conduct research, development, commercialization, and obtain regulatory approval for cancer early detection and other nucleic acid-based tests in Malaysia. The exchange of the joint agreement agreement, which took place on 6 Oct 2025 at NICE 2025 in Kuala Lumpur, was witnessed by Malaysia Deputy Prime Minister YAB Dato' Sri Fadillah bin Yusof.

Mirxes, a leading and only public-listed molecular cancer early detection company in Asia Pacific, today announced its inclusion in the Hang Seng Composite Index (HSCI), effective 8 September 2025. This significant milestone elevates the company’s market profile and enhances its strategic position within the Hong Kong and wider Asian capital markets.

Former Prime Minister Yukio Hatoyama launched a nationwide public health initiative focused on gastric health and early detection of gastric cancer in Japan, leveraging GASTROClear™. Co-initiated by Mr. Hatoyama, Mirxes Japan and Nagawa Pharmaceutical, the ambitious initiative will offer free screening to 10,000 residents across Japan.

Mirxes Holding Company Limited (the “Company”; Stock code: 2629) marked a significant milestone today as its shares debuted on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX), closing its first day of trade as a new biotech unicorn with a market capitalisation of HK$8.29 billion (US$1.06 billon).

Mirxes, a leading RNA technology company specializing in early cancer detection and precision medicine, today announced a US$40 million structured financing transaction with CBC Group’s R-Bridge Healthcare Fund (“R-Bridge”). This partnership will provide critical support for Mirxes’ ambitious growth and expansion into key global markets.

In a First-In-Singapore collaboration, leading RNA technology company Mirxes and PULSE TCM, a renowned provider of traditional Chinese Medicine (TCM) services, today launched the holistic “East Meets West” Community Health Screening Pilot at Bukit Gombak. Witnessed by Ms Low Yen Ling, Senior Minister of State, Ministry of Culture, Community and Youth, Ministry of Trade and Industry, Mayor of South West District and Grassroots Adviser to Bukit Gombak Grassroots Organisations, this pilot represents a novel approach towards integrating contemporary Western precision diagnostic technology with Eastern TCM wisdom, aimed at creating an integrated approach to preventive and personalised healthcare for a Healthier Singapore.

The National University Hospital (NUH) and Mirxes are proud to announce the official opening of the NUH DMOC@Biopolis, one of Singapore’s first publicprivate partnership centres for specialty molecular testing. The NUH DMOC@Biopolis is an extension of NUH’s Diagnostic Molecular Oncology Centre (DMOC) that co-locates and integrates with Mirxes’ clinical laboratory, M Diagnostics at Biopolis. The Centre was inaugurated today by Deputy Prime Minister, Coordinating Minister for Economic Policies, and Chairman of the National Research Foundation (NRF), Mr Heng Swee Keat.

Mirxes Corporation USA, the wholly owned subsidiary of Mirxes Pte Ltd, a Singapore-headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases accessible on a global scale, announced today that its flagship product GASTROClearTM, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S.